Coronavirus R&D Gateway

A one-stop-shop for tools and information sources supporting the ongoing efforts to defeat the Covid19 pandemic

The Coronavirus R&D Gateway is a resource for researchers, companies, policymakers and the interested public at large. The R&D Gateway has been created in cooperation with several partner organisations. It constitutes a one-stop-shop for a number of tools and information sources supporting the ongoing efforts to defeat the COVID-19 pandemic.

Subscribe to COVID-19

Latest news

Putting COVID-19 patents aside would not guarantee vaccines equity, say European Academies

14 Dec 2021

A World Trade Organisation waiver on intellectual property will not overcome immediate vaccine shortages. Compulsory licensing is a better approach

Call to put research and innovation at heart of pandemic recovery plans

18 Mar 2021

Member states have until the end of April to fine tune and adapt plans to fit with EU climate goals. But will bids to spend money on roads and gas pipelines support a green recovery?

Pandemic spurs growth of patents in pharmaceuticals and biotech, EPO says

18 Mar 2021

Live blog

LIVE BLOG: R&D response to COVID-19 pandemic

24 Aug 2020

Latest: European Commission close to advance purchase deal for 300M doses of Sanofi/Glaxo COVID-19 vaccine and says more agreements on the way

Database: Coronavirus funding opportunities

As a service to the global R&D community, Science|Business has compiled this database of funding opportunities. Users are encouraged to let us know of funding calls that could be incorporated into the database. Please email all suggestions to [email protected]. The database is updated daily.

Country

Keywords

Funder

Deadline

Latest funding opportunity:

COVID-19 in vulnerable populations, its long-term effect, and the effectiveness of remdesivir

06 Jul 2020

Projects lasting up to 9 months should collect data on the clinical course and outcome of COVID-19 in vulnerable populations, investigate long-term consequences of COVID-19 in patients, or test the safety and effectiveness of remdesivir in treating the disease.